Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: OTHER: ribociclib + ET
Sponsor: Novartis Pharmaceuticals